Your session is about to expire
← Back to Search
9-ING-41 for Pediatric Cancer
Study Summary
This trial will study whether 9-ING-41 can shrink tumors in kids with cancer without causing serious side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have recovered from previous cancer treatment side effects, except for hair loss, infertility, or hearing loss.I have recovered from side effects of my previous cancer treatments.You have had a solid organ transplant in the past.My cancer can be tracked by doctors, either by measuring it or through other tests.My cancer has come back or hasn't responded to treatment, confirmed by tests.I do not have any illnesses that would stop me from following the study's requirements.My neurological condition has been stable for a week, and if I'm on steroids, the dose hasn't increased.I am mostly able to care for myself, regardless of my age.I have undergone at least one initial treatment for my cancer.My organs and bone marrow are functioning well.I have a serious eye condition affecting my retina.You are allergic to any of the ingredients in 9-ING-41 or Irinotecan.I have no other cancers besides the one being targeted, and I'm not on other cancer treatments.I am younger than 22 years old.My condition has no cure or treatments that would extend life with good quality.
- Group 1: 9-ING-41 plus Cyclophosphamide plus Topotecan
- Group 2: 9-ING-41
- Group 3: 9-ING-41 plus Irinotecan
- Group 4: 9-ING-41 plus Irinotecan plus Temozolomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What maladies is 9-ING-41 regularly recommended to address?
"9-ING-41 is a common remedy for radiotherapy, as well as hodgkin disease, lymphocytic leukemias, and chronic granulocytic leukemia."
Could you elucidate on any past experiments involving 9-ING-41?
"First examined by City of Hope Comprehensive Cancer Center in 1997, 9-ING-41 has been the subject of 1971 clinical trials. Currently, 1272 live trials are underway; many being conducted out of Charlotte, North carolina."
Are investigators currently enrolling participants for this research project?
"According to clinicaltrials.gov, the trial is currently recruiting participants that meet its criteria. This research was first posted on June 5th 2020 and was last updated April 26th 2022."
What is the current enrollment rate for this research endeavor?
"In order to complete the trial, 68 participants who are eligible according to the criteria must be recruited. These individuals can obtain treatment at facilities like Levine Cancer Center in Charlotte, North carolina and Duke Children's Hospital and Health Center, Duke University Medical Centre in Durham, Michigan."
What potential dangers should one be aware of when using 9-ING-41?
"As this is a Phase 1 clinical trial, the safety of 9-ING-41 was tentatively rated at 1 due to limited data regarding its efficacy and security."
In how many distinct locations is this trial currently being conducted?
"Presently, 9 distinct clinics are looking for trial participants. Locations range from Ann Arbor and Durham to Charlotte, in addition to 6 other clinical sites. To reduce travel-related expenses associated with the study, we recommend selecting a clinic that is close by your location."
Share this study with friends
Copy Link
Messenger